265 related articles for article (PubMed ID: 18563057)
1. Pharmacoeconomics comes of age?
Walley T; Breckenridge A
Clin Pharmacol Ther; 2008 Aug; 84(2):279-80. PubMed ID: 18563057
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomics: the new dismal science.
Luchins DJ
Adm Policy Ment Health; 2004 May; 31(5):425-7. PubMed ID: 15379388
[No Abstract] [Full Text] [Related]
3. Will lower drug prices jeopardize drug research? A policy fact sheet.
Light DW; Lexchin J
Am J Bioeth; 2004; 4(1):W1-4. PubMed ID: 15035915
[No Abstract] [Full Text] [Related]
4. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
Schlette S; Hess R
Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
[TBL] [Abstract][Full Text] [Related]
5. [Use of pharmacoeconomics analyses to health protection].
Drozd M
Wiad Lek; 2002; 55 Suppl 1():76-9. PubMed ID: 15002222
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomics.
Ahuja J; Gupta M; Gupta AK; Kohli K
Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
[TBL] [Abstract][Full Text] [Related]
7. The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution?
Alifrangis C; Krell J; Stebbing J
Eur J Cancer; 2011 Jun; 47(9):1285-6. PubMed ID: 21550231
[No Abstract] [Full Text] [Related]
8. Pharmaceuticals in U.S. health care: determinants of quantity and price.
Berndt ER
J Econ Perspect; 2002; 16(4):45-66. PubMed ID: 15179978
[No Abstract] [Full Text] [Related]
9. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
Henry DA; Hill SR; Harris A
JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
[No Abstract] [Full Text] [Related]
10. [Pharmacoeconomics--survey and status].
Pedersen KM
Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
[TBL] [Abstract][Full Text] [Related]
11. Medicine. The intangible value of vaccination.
Rappuoli R; Miller HI; Falkow S
Science; 2002 Aug; 297(5583):937-9. PubMed ID: 12169712
[No Abstract] [Full Text] [Related]
12. Pharmacoeconomics: basic concepts and terminology.
Walley T; Haycox A
Br J Clin Pharmacol; 1997 Apr; 43(4):343-8. PubMed ID: 9146844
[No Abstract] [Full Text] [Related]
13. Investigation of comparative effectiveness research in Asia, Europe, and North America.
Patel I; Rarus R; Tan X; Lee EK; Guy J; Ahmad A; Chang J
Indian J Pharmacol; 2015; 47(6):585-93. PubMed ID: 26729947
[TBL] [Abstract][Full Text] [Related]
14. The scandal of generic drug pricing: drug regulation policies need review.
Meeran K; Choudhury SM; Wass J
BMJ; 2017 Feb; 356():j947. PubMed ID: 28232321
[No Abstract] [Full Text] [Related]
15. Potential stifling effects of pharmaco-economics and regulatory policies.
Data JL
Am J Cardiol; 1998 Apr; 81(8A):34F-35F. PubMed ID: 9604904
[No Abstract] [Full Text] [Related]
16. Drug therapy: safety, effectiveness, and economics.
Brandys J
Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340
[TBL] [Abstract][Full Text] [Related]
17. Using pharmacoeconomics to value pharmacotherapy.
Hay JW
Clin Pharmacol Ther; 2008 Aug; 84(2):197-200. PubMed ID: 18679182
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomics is coming of age.
Pizzi L; Singh V
Clin Pharmacol Ther; 2008 Aug; 84(2):188-90. PubMed ID: 18679179
[No Abstract] [Full Text] [Related]
19. The role of the pharmaceutical industry in drug development in dermatology.
Cauwenbergh G
Clin Dermatol; 2002; 20(5):467-73. PubMed ID: 12435516
[No Abstract] [Full Text] [Related]
20. Pharmacoeconomics of appropriate antimicrobial use.
Davey P
Diagn Microbiol Infect Dis; 1995; 22(1-2):225-9. PubMed ID: 7587044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
